In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on PainReform (PRFX – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $6.77.
According to TipRanks, Rahman is an analyst with an average return of -9.6% and a 33.57% success rate. Rahman covers the Healthcare sector, focusing on stocks such as PainReform, Neurosense Therapeutics Ltd., and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PainReform with a $20.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $26.41 and a one-year low of $3.40. Currently, PainReform has an average volume of 1.34M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company’s product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Read More on PRFX:
- PainReform regains compliance with Nasdaq continued listing requirements
- PainReform Regains Compliance with Nasdaq Continued Listing Requirements
- PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement
- PainReform prices $1.5M registered direct offering at $9 per share
- PainReform Ltd trading resumes
